Pleural effusion in women with a known adenocarcinoma: The role of immunostains in uncovering another hidden primary tumor

Acta Cytologica

Volumn 55, Issue 5, 2011, Pages 438-444

  Nasser, H ^a   Kuntzman, T J ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Effusion; Immunostains

Indexed keywords

CA 125 ANTIGEN; ESTROGEN RECEPTOR; MAMMAGLOBIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WILMS TUMOR ANTIGEN 1;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; COLORECTAL CANCER; CYTOLOGY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; OVARY CANCER; PERITONEUM CANCER; PLEURA EFFUSION; PRIMARY TUMOR; PRIORITY JOURNAL; STOMACH CANCER;

EID: 80155175034     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000329817     Document Type: Article

References (24)

1. Vargas FS, Teixeira LR: Pleural malignancies. Curr Opin Pulm Med 1996; 2: 335-40.
2. Dharan M: Unilateral pleural effusion as a presenting manifestation of plasma cell yeloma (multiple myeloma): a case report. Acta Cytol 2010; 54: 780-782.
3. Antic T, Staerkel G: Mediastinal epithelioid hemangioendothelioma metastatic to lymph nodes and pleural fluid: report of a case. Diagn Cytopathol 2010; 38: 113-116.
4. Inoue J, Gomibuchi H, Minoura S: A case of a primary ovarian leiomyosarcoma. J Obstet Gynaecol Res 2000; 26: 401-407.
5. Cibas ES, Ducatman BS: Cytology Diagnostic Principles and Clinical Correlates, ed 3. Philadelphia, Saunders, 2009, p 135.
6. Monte SA, Ehya H, Lang WR: Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 1987; 31: 448-452.
7. Sears D, Hajdu SI: The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987; 31: 85-97.
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
9. Fang F, Yang L, Su XL, He Q, Liu DG, Lin FR, et al: Determining the primary site of metastatic adenocarcinoma in serous fluid: a cytological study. Zhonghua Bing Li Xue Za Zhi 2005; 34: 641-645.
10. Jang KY, Kang MJ, Lee DG, Chung MJ: Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001; 23: 400-404.
11. Longatto FA, Alves VA, Kanamura CT, Nonogaki S, Bortolan J, Lombardo V, et al: Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal. Acta Cytol 2002; 46: 651-658.
12. Fiel MI, Cernaianu G, Burstein DE, Batheja N: Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol 1996; 40: 637-641.
13. Rehman F, Nagi AH, Hussain M: Immunohistochemical expression and correlation of mammaglobin with the grading system of breast carcinoma. Indian J Pathol Microbiol 2010; 53: 619-623.
14. Yang M, Nonaka D: A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654-661.
15. Vollmer RT: Primary lung cancer vs metastatic breast cancer: a probabilistic approach. Am J Clin Pathol 2009; 132: 391-395.
16. Yan Z, Gidley J, Horton D, Roberson J, Eltoum IE, Chhieng DC: Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol 2009; 37: 475-478.
17. Ashton PR, Hollingsworth AS Jr, Johnston WW: The cytopathology of metastatic breast cancer. Acta Cytol 1975; 19: 1-6.
18. Wiley EL, Von Roenn J: Metastatic breast carcinoma in pleural fluid. Correlation of morphology with estrogen receptor activity and morphology of the primary carcinoma. Acta Cytol 1990; 34: 169-174.
19. Danner DE, Gmelich JT: A comparative study of tumor cells from metastatic carcinoma of the breast in effusions. Acta Cytol 1975; 19: 509-518.
20. Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007; 35: 370-375.
21. Loy TS, Quesenberry JT, Sharp SC: Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol 1992; 98: 175-179.
22. Kim JH, Kim YS, Choi YD, Lee JS, Park CS: Utility of napsin A and thyroid transcription factor 1 in differentiating metastatic pulmonary from non-pulmonary adenocarcinoma in pleural effusion. Acta Cytol 2011; 55: 266-270.
23. Dorval M, Noguès C, Berthet P, Chiquette J, Gauthier-Villars M, Lasset C, et al: Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. Eur J Hum Genet 2011; 19: 494-499.
24. Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, et al: Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010; 102: 1874-1878.